Shares of Axovant Sciences Ltd (NASDAQ:AXON) have been assigned an average recommendation of “Hold” from the fourteen brokerages that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $11.93.
A number of equities research analysts have recently issued reports on the company. BidaskClub upgraded Axovant Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Axovant Sciences in a research report on Friday, December 1st. Oppenheimer restated a “hold” rating on shares of Axovant Sciences in a research report on Sunday, November 12th. Piper Jaffray Companies restated a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. Finally, ValuEngine lowered Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXON. Oppenheimer & Co. Inc. acquired a new position in Axovant Sciences in the third quarter valued at approximately $101,000. Cubist Systematic Strategies LLC acquired a new position in Axovant Sciences in the third quarter valued at approximately $117,000. Voya Investment Management LLC acquired a new position in Axovant Sciences in the second quarter valued at approximately $323,000. Virtus Fund Advisers LLC acquired a new position in Axovant Sciences in the fourth quarter valued at approximately $349,000. Finally, Wells Fargo & Company MN lifted its holdings in Axovant Sciences by 135.6% in the third quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock valued at $369,000 after acquiring an additional 30,905 shares during the last quarter. Hedge funds and other institutional investors own 93.52% of the company’s stock.
Shares of Axovant Sciences (AXON) opened at $1.68 on Tuesday. The company has a debt-to-equity ratio of 0.45, a current ratio of 4.58 and a quick ratio of 4.58. The stock has a market capitalization of $181.08, a P/E ratio of -0.73 and a beta of -0.97. Axovant Sciences has a 52-week low of $1.47 and a 52-week high of $27.98.
ILLEGAL ACTIVITY WARNING: “Axovant Sciences Ltd (AXON) Receives Consensus Recommendation of “Hold” from Analysts” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/axovant-sciences-ltd-axon-receives-consensus-recommendation-of-hold-from-analysts.html.
About Axovant Sciences
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.